Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05318937
Other study ID # 718-CNP-202
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date July 6, 2022
Est. completion date February 9, 2024

Study information

Verified date March 2024
Source Sage Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Parkinson's disease mild cognitive impairment (PD-MCI).


Recruitment information / eligibility

Status Completed
Enrollment 86
Est. completion date February 9, 2024
Est. primary completion date January 17, 2024
Accepts healthy volunteers No
Gender All
Age group 50 Years to 75 Years
Eligibility Inclusion Criteria: 1. Meet the following criteria for PD-MCI: Have a confirmed diagnosis of idiopathic Parkinson's disease (PD) according to 2015 Movement Disorder Society (MDS) clinical diagnostic criteria and meet MDS Task Force criteria for MCI in PD (excluding requirement for United Kingdom PD Brain Bank diagnostic criteria). 2. Meet the following criteria for MoCA: For participants meeting Level 1 PD-MCI criteria, have a Montreal Cognitive Assessment (MoCA) score of 20 to 25 (inclusive) at Screening; For participants meeting Level 2 PD-MCI criteria (within the past year), have a MoCA score of 18 to 25 (inclusive) at Screening. 3. Meet criteria for modified Hoehn & Yahr Stage I to III (mild to moderate motor severity) at Screening. 4. Have stable motor symptoms for at least 4 weeks prior to Screening, in the opinion of the investigator. 5. Must be able to complete the Color Trails Test 1 (including the ability to follow rater redirection and correct errors), and, based on participant's performance and investigator's opinion, participant is expected to be capable of engaging in prolonged cognitive testing for the duration of the study. Exclusion Criteria: 1. Have a diagnosis of dementia of any etiology, including but not limited to: Dementia with Lewy bodies, Alzheimer's dementia, and vascular dementia. 2. Have any parkinsonism other than PD, including secondary parkinsonism or atypical parkinsonism. 3. In the opinion of the investigator, be experiencing fluctuations in motor symptoms associated with PD that will interfere with completing study procedures. 4. Have an ongoing central nervous system condition other than PD that in the opinion of the investigator could influence the outcome of the study. 5. Have experienced significant psychotic symptoms, including hallucinations or delusions, within the past 3 months, in the opinion of the investigator. 6. Have a history of brain surgery, deep brain stimulation, or any history of hospitalization due to a brain injury. 7. Have a history, presence, and/or current evidence clinically relevant intracranial abnormality (e.g., stroke, hemorrhage, space-occupying lesion).

Study Design


Intervention

Drug:
SAGE-718
Softgel capsules
SAGE-718-matching placebo
Softgel capsules

Locations

Country Name City State
United States Sage Investigational Site Albany New York
United States Sage Investigational Site Bloomington Minnesota
United States Sage Investigational Site Boca Raton Florida
United States Sage Investigational Site Boca Raton Florida
United States Sage Investigational Site Burlington Vermont
United States Sage Investigational Site Chicago Illinois
United States Sage Investigational Site Cincinnati Ohio
United States Sage Investigational Site Columbus Ohio
United States Sage Investigational Site Decatur Georgia
United States Sage Investigational Site Englewood Colorado
United States Sage Investigational Site Fresno California
United States Sage Investigational Site Hialeah Florida
United States Sage Investigational Site Houston Texas
United States Sage Investigational Site Kansas City Kansas
United States Sage Investigational Site Las Vegas Nevada
United States Sage Investigational Site Little Rock Arkansas
United States Sage Investigational Site Long Beach California
United States Sage Investigational Site Los Angeles California
United States Sage Investigational Site Madison Wisconsin
United States Sage Investigational Site Memphis Tennessee
United States Sage Investigational Site Miami Florida
United States Sage Investigational Site Nashville Tennessee
United States Sage Investigational Site New York New York
United States Sage Investigational Site Orlando Florida
United States Sage Investigational Site Port Orange Florida
United States Sage Investigational Site Raleigh North Carolina
United States Sage Investigational Site Reseda California
United States Sage Investigational Site Sacramento California
United States Sage Investigational Site San Antonio Texas
United States Sage Investigational Site Stony Brook New York
United States Sage Investigational Site Sun City Arizona
United States Sage Investigational Site Tampa Florida
United States Sage Investigational Site Tampa Florida
United States Sage Investigational Site Toledo Ohio
United States Sage Investigational Site Vernon Connecticut
United States Sage Investigational Site Virginia Beach Virginia
United States Sage Investigational Site Williamsville New York
United States Sage Investigational Site Woodmere New York

Sponsors (1)

Lead Sponsor Collaborator
Sage Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline to Day 42 in the Wechsler Adult Intelligence Scale-IV (WAIS-IV) Coding Test Score WAIS-IV coding test is a valid and sensitive measure of cognitive dysfunction that correlates with real-world functional outcomes (e.g., the ability to accomplish everyday tasks) and recovery from functional disability used to assess processing speed. The participant is required to identify the symbols matched to numbers using a key and write in the symbol beneath the associated number. The total score ranges from 0 to 135 and is based on the total number of codes correctly completed over a 120-second time limit. Higher scores indicate better processing speed. Positive change from baseline indicates better processing speed. Baseline up to Day 42
Secondary Percentage of Participants with at Least One Treatment-Emergent Adverse Event (TEAE) and TEAEs by Severity Up to Day 70
Secondary Number of Participants who Withdraw Due to Adverse Events (AEs) Up to Day 70
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A
Recruiting NCT03618901 - Rock Steady Boxing vs. Sensory Attention Focused Exercise N/A